Melatonin in Depression or Anxiety

Evaluating the effects of melatonin in improving sleep quality in patients with generalized anxiety disorder or major depressive disorder

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210921052540N1

Enrollment

Registered

2021-11-04

Start date

2021-11-16

Completion date

Unknown

Last updated

2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disorder. Insomnia due to medical condition

Interventions

Intervention 1: Intervention group: Patients with in ths group will receive Melatonin 3mg every night before sleep. Intervention 2: Control group: Patients with in ths group will receive Melatonin 3mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of depression or anxiety by a doctor PSQI score above 5 GSQS score above 6

Exclusion criteria

Exclusion criteria: PSQI score less than 5 GSQS score less than 6 Patient dissatisfaction

Design outcomes

Primary

Measure	Time frame
Groningen Sleep Quality Score. Timepoint: Base line and after a month. Method of measurement: Questionnaire.;Pittsburgh Sleep Quality Index. Timepoint: Base line and after a month. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Soldouzian

Tabriz University of Medical Sciences

dr.mohammadsolduzian@gmail.com+98 41 3337 2250

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026